Johnson & Johnson (JNJ) Stock
$153.51
-1.18
(-0.76%)
Market Cap: $369.59B | NYSE
Johnson & Johnson Chart
Company Profile
Price: $153.51
Market Cap: $369.59B
Exchange: NYSE
CEO: Mr. Joaquin Duato
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 131.90K
Headquarters: New Brunswick, NJ
Website: Johnson & Johnson
Business Summary
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Johnson & Johnson News
3 Ideal Buys In 63 January Fortune 500 Industry Leaders Wherein 57 Paid Dividends And 39 Tested As 'Safer'
The June/July 2024 Fortune Magazine revealed 500 biggest U.S. companies by revenue and profits. Arnold-research focused on January industry-leaders using YCharts 1/30/25 data for profits from 63. Those 63 Fortune 500 industry leaders (F500IL) were segmented into 21 business sectors ranging (alphabetically) from aerospace/defense to wholesalers. By yield, MO topped-all F500IL. Top-ten Yields from JNJ. SO, PEP, XOM, ADM, T, CVS, UPS, ET, and MO, averaged 4.67% in January.
My Top 5 Dividend-Paying Buy-And-Hold Stocks For 2025
With both The Dividend Income Accelerator Portfolio and my personal investment portfolio I am following a buy-and-hold approach. While my private portfolio focuses on dividend growth, The Dividend Income Accelerator Portfolio balances both dividend income and dividend growth. Investing in companies with strong dividend growth potential allows you to not only benefit from annually increasing dividend payments, but also from capital appreciation.
Johnson & Johnson to Participate in the 45th Annual TD Cowen Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the 45th Annual TD Cowen Healthcare Conference on Tuesday, March 4th, 2025. Management will participate in a fireside chat at 11:10 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day.
You Deserve Reliable Income: 2 Undervalued Dividends For Long-Term Growth
A buy-and-hold strategy is ideal for investors seeking durable companies with strong dividends and attractive valuations, avoiding tax inefficiencies from frequent trading. UPS offers a 5.7% dividend yield, trading at a forward P/E of 13.5, with potential for profitability expansion despite near-term Amazon volume reductions. Johnson & Johnson, with a 3.3% dividend yield and a forward P/E of 14.4, carries a robust pipeline and 62 years of consecutive dividend growth.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson("J&J" or the "Company") (NYSE:JNJ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
US government could seek over $1 billion from J&J for cancer treatment costs
The U.S. Department of Health & Human Services may seek over $1 billion from Johnson & Johnson as reimbursement for federal health agencies' payments of medical costs for patients who allege that the company's baby powder and other talc products caused them to develop cancer, a government attorney said Friday.
Why Johnson & Johnson's Strong Buy Rating Is Justified (Rating Upgrade)
On January 22, Johnson & Johnson released financial results for the fourth quarter of 2024, which beat my expectations again. So, sales of its oncology franchise reached $5.5 billion, an increase of 19% compared to the fourth quarter of 2023. Moreover, Johnson & Johnson expects its operational sales to grow by 2% to 3% in 2025, while its adjusted diluted EPS will be between $10.50 and $10.70, implying single-digit percentage growth.
3 Stocks Upgraded by Bank of America – Here's Why They're Bullish
The new trading year is getting started, and investors might be looking to make this one either as strong as 2024 was or even stronger yet. To do this, it is always preferred to start on a strong note, meaning that the first quarter of the year has to bring about a net outperformance to give portfolios enough momentum and room to pursue some of the more aggressive growth projects later in the year.
Spravato sales surged highlights commercial viability of psychedelics, analysts believe
The latest quarterly sales figures for Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray support the notion that psychedelics can become commercially viable for mental health, analysts at Jefferies believe. Fourth quarter Spravato sales grew by 5% quarter-over-quarter to $297 million driven by increased physician and patient demand.
Why Traders Are Buying the Dip on Johnson & Johnson Stock
It is no secret that the defensive names in the stock market today, the ones not known for their hot price action or wild return potential, have been the lackluster segment of the financial markets lately. This is because the center of attention has been taken by the technology sector and some of the darling names in that space for all of 2023 and 2024.
These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024
The Dow Jones Industrial Average (DJIA) is a group of 30 U.S. industry leaders. It's often looked at as a proxy for the market, since its components' performance is indicative of what's happening in the economy and the markets.
JNJ ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Johnson & Johnson
NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning possible violations of federal securities laws. J&J issued a press release on January 8, 2025, announcing that "on January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE™ cases while we investigate the root cause of four reported neurovascular events in the U.S. External Evaluation.
Johnson & Johnson Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - JNJ
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning possible violations of federal securities laws. J&J issued a press release on January 8, 2025, announcing that "on January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE™ cases while we investigate the root cause of four reported neurovascular events in the U.S. External Evaluation.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Johnson & Johnson (JNJ) and Encourages Shareholders to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson ("J&J" or "the Company") (NYSE:JNJ). Investors who purchased J&J securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/JNJ.
Johnson & Johnson Earnings
This section highlights Johnson & Johnson's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Date:
April 15, 2025
Time:
Before Market
Est. EPS:
$2.60
Status:
Unconfirmed
Last Earnings Results
Date:
January 22, 2025
EPS:
$2.04
Est. EPS:
$1.99
Revenue:
$22.52B
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-01-22 | $1.99 | $2.04 |
| Read Transcript | Q3 | 2024 | 2024-10-15 | $2.21 | $2.42 |
| Read Transcript | Q2 | 2024 | 2024-07-17 | $2.71 | $2.82 |
| Read Transcript | Q1 | 2024 | 2024-04-16 | $2.66 | $2.71 |
| Read Transcript | Q4 | 2023 | 2024-01-23 | $2.27 | $2.29 |
| Read Transcript | Q3 | 2023 | 2023-10-17 | $2.52 | $2.66 |
| Read Transcript | Q2 | 2023 | 2023-07-20 | $2.61 | $2.80 |
| Read Transcript | Q1 | 2023 | 2023-04-18 | $2.51 | $2.68 |
Financial Statements
Access annual & quarterly financial statements for Johnson & Johnson, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2023 | January 01, 2023 | January 02, 2022 | January 03, 2021 | December 29, 2019 |
|---|---|---|---|---|---|
| Revenue | $85.16B | $79.99B | $78.74B | $82.58B | $82.06B |
| Cost of Revenue | $26.55B | $24.60B | $23.40B | $28.43B | $27.56B |
| Gross Profit | $58.61B | $55.39B | $55.34B | $54.16B | $54.50B |
| Gross Profit Ratio | 68.82% | 69.25% | 70.28% | 65.58% | 66.42% |
| Research and Development Expenses | $15.05B | $14.13B | $14.28B | $12.34B | $11.36B |
| General and Administrative Expenses | $20.11B | $19.05B | $20.12B | $22.08B | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $20.11B | $19.05B | $20.12B | $22.08B | $22.18B |
| Other Expenses | $- | $500.00M | $-526.00M | $-2.90B | $-2.52B |
| Operating Expenses | $35.56B | $33.18B | $34.40B | $34.42B | $33.53B |
| Cost and Expenses | $61.81B | $57.78B | $57.80B | $62.85B | $61.09B |
| Interest Income | $1.26B | $490.00M | $53.00M | $111.00M | $357.00M |
| Interest Expense | $772.00M | $276.00M | $183.00M | $201.00M | $318.00M |
| Depreciation and Amortization | $7.49B | $6.97B | $7.39B | $7.23B | $7.01B |
| EBITDA | $23.73B | $27.17B | $30.93B | $27.50B | $28.27B |
| EBITDA Ratio | 27.86% | 37.71% | 35.38% | 29.27% | 26.96% |
| Operating Income | $23.41B | $23.19B | $20.47B | $16.95B | $15.12B |
| Operating Income Ratio | 27.49% | 28.99% | 26.00% | 20.52% | 18.42% |
| Total Other Income Expenses Net | $-8.35B | $-2.85B | $-1.76B | $-3.24B | $2.21B |
| Income Before Tax | $15.06B | $19.36B | $19.18B | $16.50B | $17.33B |
| Income Before Tax Ratio | 17.69% | 24.20% | 24.36% | 19.98% | 21.12% |
| Income Tax Expense | $1.74B | $2.99B | $1.38B | $1.78B | $2.21B |
| Net Income | $35.15B | $17.94B | $20.88B | $14.71B | $15.12B |
| Net Income Ratio | 41.28% | 22.43% | 26.52% | 17.82% | 18.42% |
| EPS | $13.88 | $6.86 | $7.93 | $5.59 | $5.74 |
| EPS Diluted | $13.73 | $6.73 | $7.81 | $5.51 | $5.63 |
| Weighted Average Shares Outstanding | 2.53B | 2.61B | 2.63B | 2.63B | 2.63B |
| Weighted Average Shares Outstanding Diluted | 2.56B | 2.66B | 2.67B | 2.67B | 2.68B |
| SEC Filing | Source | Source | Source | Source | Source |
Income Statement Charts
| Breakdown | September 29, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | October 01, 2023 | July 02, 2023 | April 02, 2023 | January 01, 2023 | October 02, 2022 | July 03, 2022 | April 03, 2022 | January 02, 2022 | October 03, 2021 | July 04, 2021 | April 04, 2021 | January 03, 2021 | September 27, 2020 | June 28, 2020 | March 29, 2020 | December 29, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22.47B | $22.45B | $21.38B | $21.39B | $21.35B | $21.52B | $20.89B | $23.71B | $20.00B | $24.02B | $23.43B | $24.80B | $23.34B | $23.31B | $22.32B | $22.48B | $21.08B | $18.34B | $20.69B | $20.75B |
| Cost of Revenue | $6.96B | $6.87B | $6.51B | $6.80B | $6.61B | $6.46B | $6.69B | $7.76B | $6.17B | $7.92B | $7.60B | $7.96B | $7.25B | $7.59B | $7.06B | $7.81B | $6.97B | $6.58B | $7.06B | $7.13B |
| Gross Profit | $15.51B | $15.58B | $14.87B | $14.60B | $14.74B | $15.06B | $14.21B | $15.94B | $13.82B | $16.10B | $15.83B | $16.85B | $16.09B | $15.72B | $15.26B | $14.66B | $14.11B | $11.76B | $13.63B | $13.61B |
| Gross Profit Ratio | 69.01% | 69.40% | 69.55% | 68.23% | 69.06% | 69.97% | 68.00% | 67.24% | 69.13% | 67.03% | 67.57% | 67.93% | 68.93% | 67.45% | 68.36% | 65.23% | 66.93% | 64.12% | 65.87% | 65.61% |
| Research and Development Expenses | $4.95B | $3.44B | $3.54B | $4.48B | $3.45B | $3.70B | $3.46B | $4.62B | $3.48B | $3.70B | $4.07B | $4.72B | $3.42B | $3.39B | $3.18B | $4.03B | $2.84B | $2.71B | $2.58B | $3.23B |
| General and Administrative Expenses | $- | $5.48B | $5.06B | $5.51B | $5.10B | $5.00B | $4.51B | $- | $- | $- | $5.64B | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $5.28B | $5.48B | $5.06B | $5.51B | $5.10B | $5.00B | $4.51B | $6.51B | $4.97B | $6.23B | $5.64B | $7.15B | $6.00B | $6.07B | $5.43B | $6.46B | $5.43B | $4.99B | $5.20B | $6.04B |
| Other Expenses | $- | $400.00M | $200.00M | $100.00M | $100.00M | $100.00M | $-100.00M | $-3.27B | $400.00M | $500.00M | $300.00M | $-1.39B | $100.00M | $300.00M | $400.00M | $-3.40B | $300.00M | $-24.00M | $679.00M | $-16.00M |
| Operating Expenses | $10.43B | $8.92B | $8.60B | $9.99B | $8.55B | $8.70B | $7.96B | $11.14B | $8.46B | $9.93B | $9.71B | $11.87B | $9.42B | $9.47B | $8.61B | $10.49B | $8.27B | $7.70B | $7.78B | $9.27B |
| Cost and Expenses | $17.21B | $15.79B | $15.11B | $16.79B | $15.15B | $15.16B | $14.65B | $18.90B | $14.63B | $17.85B | $17.31B | $19.83B | $16.67B | $17.05B | $15.67B | $18.30B | $15.24B | $14.28B | $14.85B | $16.41B |
| Interest Income | $292.00M | $395.00M | $364.00M | $363.00M | $374.00M | $326.00M | $198.00M | $254.00M | $150.00M | $64.00M | $22.00M | $13.00M | $13.00M | $12.00M | $15.00M | $13.00M | $12.00M | $19.00M | $67.00M | $81.00M |
| Interest Expense | $193.00M | $270.00M | $155.00M | $151.00M | $192.00M | $217.00M | $212.00M | $177.00M | $51.00M | $38.00M | $10.00M | $60.00M | $20.00M | $40.00M | $63.00M | $87.00M | $44.00M | $45.00M | $25.00M | $85.00M |
| Depreciation and Amortization | $1.85B | $1.78B | $1.81B | $1.84B | $1.83B | $1.93B | $1.88B | $1.77B | $1.69B | $1.74B | $1.77B | $1.84B | $1.81B | $1.84B | $1.89B | $1.94B | $1.82B | $1.73B | $1.75B | $1.82B |
| EBITDA | $5.48B | $8.48B | $8.65B | $6.90B | $8.21B | $8.70B | $1.50B | $6.27B | $7.57B | $8.51B | $8.50B | $5.52B | $8.65B | $8.40B | $8.94B | $6.19B | $7.78B | $5.89B | $8.34B | $6.22B |
| EBITDA Ratio | 24.40% | 41.35% | 40.44% | 32.41% | 39.82% | 40.44% | 39.17% | 14.87% | 37.87% | 35.42% | 35.05% | 22.26% | 37.03% | 36.02% | 40.05% | 12.33% | 37.80% | 31.51% | 40.30% | 29.99% |
| Operating Income | $2.69B | $7.50B | $6.83B | $5.09B | $6.67B | $6.77B | $6.30B | $1.75B | $5.89B | $6.76B | $6.44B | $3.68B | $6.83B | $6.56B | $7.04B | $831.00M | $6.15B | $4.05B | $6.59B | $4.41B |
| Operating Income Ratio | 11.99% | 33.41% | 31.96% | 23.80% | 31.25% | 31.45% | 30.17% | 7.39% | 29.45% | 28.16% | 27.50% | 14.83% | 29.26% | 28.13% | 31.56% | 3.70% | 29.18% | 22.10% | 31.86% | 21.24% |
| Total Other Income Expenses Net | $644.00M | $-909.00M | $-2.56B | $219.00M | $-981.00M | $-52.00M | $-7.53B | $296.00M | $-492.00M | $-332.00M | $-256.00M | $72.00M | $-2.82B | $404.00M | $781.00M | $816.00M | $-1.54B | $-117.00M | $-83.00M | $-124.00M |
| Income Before Tax | $3.34B | $5.75B | $3.71B | $4.83B | $5.22B | $6.31B | $-1.29B | $4.20B | $5.17B | $5.84B | $5.86B | $4.84B | $3.85B | $6.66B | $7.43B | $1.65B | $4.40B | $3.94B | $6.51B | $4.22B |
| Income Before Tax Ratio | 14.85% | 25.61% | 17.37% | 22.56% | 24.43% | 29.30% | -6.16% | 17.72% | 25.87% | 24.31% | 25.02% | 19.50% | 16.49% | 28.58% | 33.28% | 7.33% | 20.88% | 21.49% | 31.46% | 20.33% |
| Income Tax Expense | $644.00M | $1.06B | $459.00M | $694.00M | $908.00M | $930.00M | $-796.00M | $681.00M | $862.00M | $1.03B | $713.00M | $100.00M | $182.00M | $384.00M | $1.23B | $-91.00M | $847.00M | $314.00M | $713.00M | $208.00M |
| Net Income | $2.69B | $4.69B | $3.25B | $4.05B | $26.03B | $5.14B | $-68.00M | $3.52B | $4.46B | $4.81B | $5.15B | $4.74B | $3.67B | $6.28B | $6.20B | $1.74B | $3.55B | $3.63B | $5.80B | $4.01B |
| Net Income Ratio | 11.99% | 20.88% | 15.22% | 18.92% | 121.91% | 23.90% | -0.33% | 14.85% | 22.29% | 20.04% | 21.98% | 19.09% | 15.71% | 26.93% | 27.76% | 7.73% | 16.86% | 19.78% | 28.01% | 19.33% |
| EPS | $1.12 | $1.95 | $1.35 | $1.68 | $10.32 | $1.98 | $-0.03 | $1.35 | $1.70 | $1.83 | $1.96 | $1.80 | $1.39 | $2.38 | $2.35 | $0.66 | $1.35 | $1.38 | $2.20 | $1.52 |
| EPS Diluted | $1.11 | $1.93 | $1.34 | $1.67 | $10.21 | $1.96 | $-0.03 | $1.33 | $1.68 | $1.80 | $1.93 | $1.77 | $1.37 | $2.35 | $2.32 | $0.65 | $1.33 | $1.36 | $2.17 | $1.50 |
| Weighted Average Shares Outstanding | 2.41B | 2.41B | 2.41B | 2.41B | 2.52B | 2.60B | 2.61B | 2.61B | 2.62B | 2.63B | 2.63B | 2.63B | 2.63B | 2.63B | 2.63B | 2.63B | 2.63B | 2.63B | 2.63B | 2.63B |
| Weighted Average Shares Outstanding Diluted | 2.43B | 2.42B | 2.43B | 2.43B | 2.55B | 2.63B | 2.61B | 2.66B | 2.66B | 2.67B | 2.67B | 2.67B | 2.67B | 2.67B | 2.67B | 2.67B | 2.67B | 2.67B | 2.67B | 2.67B |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2023 | January 01, 2023 | January 02, 2022 | January 03, 2021 | December 29, 2019 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $21.86B | $12.89B | $14.49B | $13.98B | $17.30B |
| Short Term Investments | $1.07B | $9.39B | $17.12B | $11.20B | $1.98B |
| Cash and Short Term Investments | $22.93B | $22.28B | $31.61B | $25.18B | $19.29B |
| Net Receivables | $14.87B | $14.04B | $15.28B | $13.58B | $14.48B |
| Inventory | $11.18B | $10.27B | $10.39B | $9.34B | $9.02B |
| Other Current Assets | $4.51B | $8.71B | $3.70B | $3.13B | $2.49B |
| Total Current Assets | $53.49B | $55.29B | $60.98B | $51.24B | $45.27B |
| Property Plant Equipment Net | $19.90B | $17.98B | $18.96B | $18.77B | $17.66B |
| Goodwill | $36.56B | $36.05B | $35.25B | $36.39B | $33.64B |
| Intangible Assets | $34.17B | $38.49B | $46.39B | $53.40B | $47.64B |
| Goodwill and Intangible Assets | $70.73B | $74.54B | $81.64B | $89.80B | $81.28B |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $9.28B | $8.95B | $10.22B | $8.53B | $7.82B |
| Other Non-Current Assets | $14.15B | $30.62B | $10.22B | $6.56B | $5.70B |
| Total Non-Current Assets | $114.06B | $132.08B | $121.04B | $123.66B | $112.45B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $167.56B | $187.38B | $182.02B | $174.89B | $157.73B |
| Account Payables | $9.63B | $9.89B | $11.05B | $9.51B | $8.54B |
| Short Term Debt | $3.45B | $12.76B | $3.77B | $2.63B | $1.20B |
| Tax Payables | $2.99B | $2.22B | $1.11B | $1.39B | $2.27B |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $30.21B | $30.94B | $29.29B | $28.96B | $23.95B |
| Total Current Liabilities | $46.28B | $55.80B | $45.23B | $42.49B | $35.96B |
| Long Term Debt | $26.98B | $27.99B | $29.98B | $32.63B | $26.49B |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $3.19B | $3.99B | $7.49B | $7.21B | $5.96B |
| Other Non-Current Liabilities | $22.33B | $22.80B | $25.30B | $29.27B | $29.84B |
| Total Non-Current Liabilities | $52.50B | $54.77B | $62.77B | $69.12B | $62.29B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $98.78B | $110.57B | $108.00B | $111.62B | $98.26B |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B |
| Retained Earnings | $153.84B | $128.34B | $123.06B | $113.89B | $110.66B |
| Accumulated Other Comprehensive Income Loss | $-12.53B | $-12.97B | $-13.06B | $-15.24B | $-15.89B |
| Other Total Stockholders Equity | $-75.66B | $-41.69B | $-39.10B | $-38.49B | $-38.42B |
| Total Stockholders Equity | $68.77B | $76.80B | $74.02B | $63.28B | $59.47B |
| Total Equity | $68.77B | $76.80B | $74.02B | $63.28B | $59.47B |
| Total Liabilities and Stockholders Equity | $167.56B | $187.38B | $182.02B | $174.89B | $157.73B |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $167.56B | $187.38B | $182.02B | $174.89B | $157.73B |
| Total Investments | $1.07B | $9.39B | $17.12B | $11.20B | $1.98B |
| Total Debt | $29.33B | $39.64B | $33.75B | $35.27B | $27.70B |
| Net Debt | $7.47B | $26.75B | $19.26B | $21.28B | $10.39B |
Balance Sheet Charts
| Breakdown | September 29, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | October 01, 2023 | July 02, 2023 | April 02, 2023 | January 01, 2023 | October 02, 2022 | July 03, 2022 | April 03, 2022 | January 02, 2022 | October 03, 2021 | July 04, 2021 | April 04, 2021 | January 03, 2021 | September 27, 2020 | June 28, 2020 | March 29, 2020 | December 29, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $19.98B | $24.88B | $25.47B | $21.86B | $19.73B | $21.18B | $19.17B | $12.89B | $11.36B | $10.98B | $10.46B | $14.49B | $17.60B | $14.33B | $12.67B | $13.98B | $18.96B | $11.17B | $15.53B | $17.30B |
| Short Term Investments | $317.00M | $597.00M | $745.00M | $1.07B | $3.78B | $7.32B | $5.44B | $9.39B | $22.72B | $21.59B | $19.93B | $17.12B | $13.40B | $10.97B | $11.95B | $11.20B | $11.82B | $7.96B | $2.49B | $1.98B |
| Cash and Short Term Investments | $20.30B | $25.48B | $26.22B | $22.93B | $23.51B | $28.50B | $24.61B | $22.28B | $34.08B | $32.57B | $30.39B | $31.61B | $31.00B | $25.31B | $24.62B | $25.18B | $30.78B | $19.14B | $18.02B | $19.29B |
| Net Receivables | $16.17B | $15.79B | $14.95B | $14.87B | $14.80B | $16.78B | $16.35B | $14.04B | $15.89B | $16.14B | $15.59B | $15.28B | $14.91B | $14.87B | $14.94B | $13.58B | $14.58B | $14.64B | $14.87B | $14.48B |
| Inventory | $12.60B | $12.17B | $11.38B | $11.18B | $11.20B | $12.89B | $12.81B | $10.27B | $11.68B | $11.44B | $10.99B | $10.39B | $10.39B | $10.10B | $9.95B | $9.34B | $9.60B | $9.42B | $8.87B | $9.02B |
| Other Current Assets | $4.17B | $4.38B | $4.46B | $4.51B | $4.20B | $2.40B | $10.62B | $8.71B | $3.59B | $3.70B | $3.45B | $3.70B | $3.59B | $3.49B | $3.02B | $3.13B | $2.62B | $2.69B | $2.46B | $2.49B |
| Total Current Assets | $53.25B | $57.82B | $57.00B | $53.49B | $53.70B | $60.57B | $64.39B | $55.29B | $65.24B | $63.85B | $60.42B | $60.98B | $59.89B | $53.77B | $52.53B | $51.24B | $57.58B | $45.89B | $44.23B | $45.27B |
| Property Plant Equipment Net | $20.48B | $19.75B | $19.63B | $19.90B | $18.82B | $20.58B | $20.17B | $17.98B | $18.15B | $18.35B | $18.70B | $18.96B | $18.48B | $18.63B | $18.37B | $18.77B | $17.86B | $17.60B | $17.40B | $17.66B |
| Goodwill | $44.80B | $44.25B | $36.62B | $36.56B | $36.12B | $45.44B | $45.58B | $36.05B | $33.38B | $34.17B | $34.94B | $35.25B | $35.57B | $35.82B | $35.69B | $36.39B | $34.31B | $33.89B | $33.47B | $33.64B |
| Intangible Assets | $39.49B | $39.73B | $34.29B | $34.17B | $35.02B | $46.25B | $47.45B | $38.49B | $40.34B | $42.41B | $44.42B | $46.39B | $47.78B | $50.24B | $51.11B | $53.40B | $47.01B | $47.41B | $47.34B | $47.64B |
| Goodwill and Intangible Assets | $84.29B | $83.97B | $70.90B | $70.73B | $71.14B | $91.69B | $93.02B | $74.54B | $73.72B | $76.57B | $79.36B | $81.64B | $83.34B | $86.06B | $86.80B | $89.80B | $81.31B | $81.30B | $80.81B | $81.28B |
| Long Term Investments | $- | $1.14B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $9.35B | $9.00B | $10.30B | $9.28B | $9.26B | $8.78B | $8.82B | $8.95B | $9.39B | $9.51B | $9.94B | $10.22B | $10.65B | $10.80B | $8.32B | $8.53B | $7.82B | $7.80B | $7.54B | $7.82B |
| Other Non-Current Assets | $10.92B | $9.40B | $14.12B | $14.15B | $13.13B | $10.08B | $9.57B | $30.62B | $8.62B | $9.44B | $9.94B | $10.22B | $6.87B | $7.17B | $6.54B | $6.56B | $6.13B | $5.78B | $5.04B | $5.70B |
| Total Non-Current Assets | $125.04B | $123.27B | $114.96B | $114.06B | $112.36B | $131.12B | $131.58B | $132.08B | $109.89B | $113.88B | $117.93B | $121.04B | $119.34B | $122.67B | $120.02B | $123.66B | $113.11B | $112.49B | $110.79B | $112.45B |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $178.29B | $181.09B | $171.97B | $167.56B | $166.06B | $191.69B | $195.97B | $187.38B | $175.12B | $177.72B | $178.35B | $182.02B | $179.23B | $176.44B | $172.56B | $174.89B | $170.69B | $158.38B | $155.02B | $157.73B |
| Account Payables | $8.95B | $8.85B | $8.17B | $9.63B | $8.36B | $10.44B | $9.91B | $9.89B | $10.15B | $9.77B | $9.31B | $11.05B | $8.96B | $8.70B | $8.50B | $9.51B | $7.04B | $6.76B | $7.41B | $8.54B |
| Short Term Debt | $4.46B | $9.86B | $8.55B | $3.45B | $3.87B | $11.70B | $17.98B | $12.76B | $4.42B | $4.30B | $4.30B | $3.77B | $3.80B | $3.17B | $3.35B | $2.63B | $5.08B | $5.33B | $2.19B | $1.20B |
| Tax Payables | $4.83B | $4.31B | $3.32B | $2.99B | $2.90B | $2.69B | $4.27B | $2.22B | $1.99B | $1.98B | $1.71B | $1.11B | $2.16B | $1.20B | $1.88B | $1.39B | $1.67B | $1.63B | $1.93B | $2.27B |
| Deferred Revenue | $- | $4.31B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $33.51B | $30.92B | $28.68B | $30.21B | $29.25B | $29.34B | $28.22B | $30.94B | $28.98B | $28.77B | $28.08B | $29.29B | $29.64B | $25.64B | $27.20B | $28.96B | $25.06B | $23.04B | $22.16B | $23.95B |
| Total Current Liabilities | $51.76B | $53.93B | $48.73B | $46.28B | $44.37B | $54.17B | $60.37B | $55.80B | $45.54B | $44.82B | $43.39B | $45.23B | $44.56B | $38.72B | $40.93B | $42.49B | $38.85B | $36.77B | $33.69B | $35.96B |
| Long Term Debt | $31.29B | $31.64B | $25.08B | $25.88B | $26.05B | $33.90B | $34.93B | $27.99B | $27.60B | $28.29B | $28.85B | $29.98B | $30.13B | $30.31B | $30.26B | $32.63B | $32.68B | $25.06B | $25.39B | $26.49B |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $2.95B | $2.63B | $3.17B | $3.19B | $2.62B | $3.63B | $4.42B | $3.99B | $4.95B | $5.01B | $6.42B | $7.49B | $7.15B | $9.02B | $6.51B | $7.21B | $5.62B | $5.53B | $5.77B | $5.96B |
| Other Non-Current Liabilities | $22.13B | $21.35B | $24.97B | $23.43B | $21.79B | $23.58B | $25.38B | $26.79B | $22.43B | $23.24B | $24.98B | $25.30B | $27.12B | $28.81B | $29.02B | $29.27B | $29.08B | $28.04B | $28.88B | $29.84B |
| Total Non-Current Liabilities | $56.37B | $55.62B | $53.22B | $52.50B | $50.46B | $61.11B | $64.73B | $54.77B | $54.98B | $56.55B | $60.26B | $62.77B | $64.39B | $68.14B | $65.79B | $69.12B | $67.37B | $58.63B | $60.03B | $62.29B |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $108.13B | $109.55B | $101.95B | $98.78B | $94.83B | $115.28B | $125.10B | $110.57B | $100.53B | $101.37B | $103.65B | $108.00B | $108.96B | $106.86B | $106.72B | $111.62B | $106.22B | $95.40B | $93.72B | $98.26B |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B | $3.12B |
| Retained Earnings | $155.18B | $155.36B | $153.38B | $153.84B | $152.54B | $129.38B | $124.56B | $128.34B | $127.92B | $126.22B | $124.38B | $123.06B | $121.09B | $120.15B | $116.51B | $113.89B | $114.83B | $113.90B | $112.90B | $110.66B |
| Accumulated Other Comprehensive Income Loss | $-12.52B | $-11.25B | $-10.77B | $-12.53B | $-8.78B | $-13.13B | $-12.63B | $-12.97B | $-15.29B | $-13.84B | $-13.76B | $-13.06B | $-15.41B | $-15.10B | $-15.33B | $-15.24B | $-14.94B | $-15.53B | $-16.24B | $-15.89B |
| Other Total Stockholders Equity | $-75.62B | $-75.69B | $-75.71B | $-75.66B | $-75.65B | $-44.22B | $-44.18B | $-41.69B | $-41.15B | $-39.14B | $-39.03B | $-39.10B | $-38.52B | $-38.59B | $-38.47B | $-38.49B | $-38.54B | $-38.51B | $-38.48B | $-38.42B |
| Total Stockholders Equity | $70.16B | $71.54B | $70.02B | $68.77B | $71.23B | $75.15B | $70.87B | $76.80B | $74.60B | $76.36B | $74.71B | $74.02B | $70.27B | $69.58B | $65.83B | $63.28B | $64.47B | $62.98B | $61.29B | $59.47B |
| Total Equity | $70.16B | $71.54B | $70.02B | $68.77B | $71.23B | $76.41B | $70.87B | $76.80B | $74.60B | $76.36B | $74.71B | $74.02B | $70.27B | $69.58B | $65.83B | $63.28B | $64.47B | $62.98B | $61.29B | $59.47B |
| Total Liabilities and Stockholders Equity | $178.29B | $181.09B | $171.97B | $167.56B | $166.06B | $191.69B | $195.97B | $187.38B | $175.12B | $177.72B | $178.35B | $182.02B | $179.23B | $176.44B | $172.56B | $174.89B | $170.69B | $158.38B | $155.02B | $157.73B |
| Minority Interest | $- | $- | $- | $- | $- | $1.26B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $178.29B | $181.09B | $171.97B | $167.56B | $166.06B | $191.69B | $195.97B | $187.38B | $175.12B | $177.72B | $178.35B | $182.02B | $179.23B | $176.44B | $172.56B | $174.89B | $170.69B | $158.38B | $155.02B | $157.73B |
| Total Investments | $317.00M | $597.00M | $745.00M | $1.07B | $3.78B | $7.32B | $5.44B | $9.39B | $22.72B | $21.59B | $19.93B | $17.12B | $13.40B | $10.97B | $11.95B | $11.20B | $11.82B | $7.96B | $2.49B | $1.98B |
| Total Debt | $35.75B | $41.49B | $33.63B | $29.33B | $29.92B | $45.60B | $52.91B | $39.64B | $32.03B | $32.60B | $33.15B | $33.75B | $33.93B | $33.48B | $33.61B | $35.27B | $37.76B | $30.39B | $27.58B | $27.70B |
| Net Debt | $15.77B | $16.61B | $8.16B | $7.47B | $10.19B | $24.42B | $33.74B | $26.75B | $20.67B | $21.61B | $22.68B | $19.26B | $16.32B | $19.15B | $20.94B | $21.28B | $18.79B | $19.22B | $12.05B | $10.39B |
Annual Cash Flow
| Breakdown | December 31, 2023 | January 01, 2023 | January 02, 2022 | January 03, 2021 | December 29, 2019 |
|---|---|---|---|---|---|
| Net Income | $13.33B | $17.94B | $20.88B | $14.71B | $15.12B |
| Depreciation and Amortization | $7.49B | $6.97B | $7.39B | $7.23B | $7.01B |
| Deferred Income Tax | $-4.19B | $-1.66B | $-2.08B | $-1.14B | $-2.48B |
| Stock Based Compensation | $1.16B | $1.14B | $1.14B | $1.00B | $977.00M |
| Change in Working Capital | $2.51B | $-4.01B | $-4.24B | $2.69B | $3.87B |
| Accounts Receivables | $-624.00M | $-1.29B | $-2.40B | $774.00M | $-289.00M |
| Inventory | $-1.32B | $-2.53B | $-1.25B | $-265.00M | $-277.00M |
| Accounts Payables | $2.35B | $1.10B | $2.44B | $5.14B | $4.06B |
| Other Working Capital | $2.11B | $-1.29B | $-3.02B | $-2.96B | $371.00M |
| Other Non Cash Items | $2.50B | $819.00M | $324.00M | $-963.00M | $-1.08B |
| Net Cash Provided by Operating Activities | $22.79B | $21.19B | $23.41B | $23.54B | $23.42B |
| Investments in Property Plant and Equipment | $-4.54B | $-4.01B | $-3.65B | $-3.35B | $-3.50B |
| Acquisitions Net | $- | $-17.65B | $-60.00M | $-7.32B | $-5.81B |
| Purchases of Investments | $-10.91B | $-32.38B | $-30.39B | $-21.09B | $-3.92B |
| Sales Maturities of Investments | $19.39B | $41.61B | $25.01B | $12.14B | $3.73B |
| Other Investing Activities | $-3.06B | $65.00M | $417.00M | $-1.20B | $3.31B |
| Net Cash Used for Investing Activities | $878.00M | $-12.37B | $-8.68B | $-20.82B | $-6.19B |
| Debt Repayment | $-2.73B | $-2.13B | $-990.00M | $7.09B | $-2.88B |
| Common Stock Issued | $4.24B | $- | $- | $- | $- |
| Common Stock Repurchased | $-5.05B | $-6.04B | $-3.46B | $-3.22B | $-6.75B |
| Dividends Paid | $-11.77B | $-11.68B | $-11.03B | $-10.48B | $-9.92B |
| Other Financing Activities | $-508.00M | $10.98B | $1.43B | $487.00M | $1.53B |
| Net Cash Used Provided by Financing Activities | $-15.82B | $-8.87B | $-14.05B | $-6.12B | $-18.02B |
| Effect of Forex Changes on Cash | $-112.00M | $-312.00M | $-178.00M | $89.00M | $-9.00M |
| Net Change in Cash | $7.73B | $-360.00M | $502.00M | $-3.32B | $-802.00M |
| Cash at End of Period | $21.86B | $14.13B | $14.49B | $13.98B | $17.30B |
| Cash at Beginning of Period | $14.13B | $14.49B | $13.98B | $17.30B | $18.11B |
| Operating Cash Flow | $22.79B | $21.19B | $23.41B | $23.54B | $23.42B |
| Capital Expenditure | $-4.54B | $-4.01B | $-3.65B | $-3.35B | $-3.50B |
| Free Cash Flow | $18.25B | $17.18B | $19.76B | $20.19B | $19.92B |
Cash Flow Charts
| Breakdown | September 29, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | October 01, 2023 | July 02, 2023 | April 02, 2023 | January 01, 2023 | October 02, 2022 | July 03, 2022 | April 03, 2022 | January 02, 2022 | October 03, 2021 | July 04, 2021 | April 04, 2021 | January 03, 2021 | September 27, 2020 | June 28, 2020 | March 29, 2020 | December 29, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $2.69B | $4.69B | $3.25B | $4.13B | $4.31B | $5.14B | $-68.00M | $3.52B | $4.46B | $4.81B | $5.15B | $4.74B | $3.67B | $6.28B | $6.20B | $1.74B | $3.55B | $3.63B | $5.80B | $4.01B |
| Depreciation and Amortization | $1.85B | $1.78B | $1.81B | $1.84B | $1.83B | $1.93B | $1.88B | $1.77B | $1.69B | $1.74B | $1.77B | $1.84B | $1.81B | $1.84B | $1.89B | $1.94B | $1.82B | $1.73B | $1.75B | $1.82B |
| Deferred Income Tax | $90.00M | $-695.00M | $-1.56B | $-2.41B | $560.00M | $-799.00M | $-1.54B | $825.00M | $-139.00M | $-1.42B | $-926.00M | $485.00M | $-1.88B | $45.00M | $-730.00M | $-903.00M | $190.00M | $-482.00M | $54.00M | $-350.00M |
| Stock Based Compensation | $295.00M | $341.00M | $302.00M | $178.00M | $296.00M | $382.00M | $306.00M | $213.00M | $281.00M | $647.00M | $278.00M | $215.00M | $259.00M | $354.00M | $307.00M | $160.00M | $256.00M | $326.00M | $263.00M | $160.00M |
| Change in Working Capital | $1.83B | $-452.00M | $-338.00M | $3.25B | $-602.00M | $-2.40B | $2.26B | $-1.24B | $-30.00M | $-3.00M | $-2.74B | $-1.57B | $3.50B | $-3.15B | $-3.02B | $5.43B | $2.61B | $-1.80B | $-3.55B | $719.00M |
| Accounts Receivables | $-96.00M | $-884.00M | $-279.00M | $227.00M | $-252.00M | $-545.00M | $-54.00M | $301.00M | $-205.00M | $-959.00M | $-427.00M | $-584.00M | $-252.00M | $38.00M | $-1.60B | $1.21B | $80.00M | $292.00M | $-812.00M | $376.00M |
| Inventory | $-299.00M | $-391.00M | $-348.00M | $124.00M | $-706.00M | $-217.00M | $-524.00M | $-650.00M | $-620.00M | $-657.00M | $-600.00M | $-70.00M | $-360.00M | $-123.00M | $-695.00M | $519.00M | $-147.00M | $-478.00M | $-159.00M | $147.00M |
| Accounts Payables | $- | $2.93B | $-2.48B | $1.68B | $1.73B | $1.51B | $-2.57B | $957.00M | $1.31B | $1.65B | $-2.82B | $2.25B | $-11.22B | $-18.12B | $-2.34B | $-5.04B | $-16.06B | $-10.73B | $-2.52B | $-9.11B |
| Other Working Capital | $2.22B | $-2.11B | $2.77B | $1.21B | $-1.37B | $-3.15B | $5.41B | $-1.85B | $-516.00M | $-34.00M | $1.10B | $-914.00M | $15.33B | $15.05B | $1.62B | $8.74B | $18.73B | $9.12B | $-58.00M | $9.31B |
| Other Non Cash Items | $1.24B | $2.22B | $7.23B | $875.00M | $1.10B | $-78.00M | $419.00M | $259.00M | $29.00M | $83.00M | $448.00M | $21.00M | $930.00M | $-48.00M | $-579.00M | $-27.00M | $-43.00M | $57.00M | $-950.00M | $43.00M |
| Net Cash Provided by Operating Activities | $7.99B | $5.63B | $3.66B | $7.86B | $7.49B | $4.18B | $3.26B | $5.35B | $6.28B | $5.58B | $3.98B | $5.73B | $8.29B | $5.31B | $4.07B | $8.34B | $8.38B | $3.45B | $3.36B | $6.40B |
| Investments in Property Plant and Equipment | $-1.84B | $-976.00M | $-807.00M | $-1.59B | $-967.00M | $-1.12B | $-863.00M | $-1.59B | $-952.00M | $-863.00M | $-607.00M | $-1.42B | $-747.00M | $-813.00M | $-677.00M | $-1.32B | $-737.00M | $-662.00M | $-625.00M | $-1.26B |
| Acquisitions Net | $-338.00M | $-12.63B | $-1.60B | $121.00M | $121.00M | $76.00M | $40.00M | $-17.13B | $1.00M | $-271.00M | $-252.00M | $-60.00M | $12.00M | $51.00M | $- | $-6.37B | $- | $-10.00M | $-939.00M | $-248.00M |
| Purchases of Investments | $-280.00M | $-554.00M | $-630.00M | $-925.00M | $-293.00M | $-5.91B | $-3.77B | $-1.22B | $-9.11B | $-13.04B | $-9.02B | $-11.55B | $-6.58B | $-6.27B | $-5.99B | $-4.85B | $-7.69B | $-6.49B | $-2.06B | $-1.24B |
| Sales Maturities of Investments | $466.00M | $727.00M | $979.00M | $3.60B | $3.91B | $4.11B | $7.77B | $15.29B | $8.69B | $11.33B | $6.30B | $8.20B | $4.36B | $7.22B | $5.23B | $5.43B | $3.62B | $-198.00M | $3.29B | $1.27B |
| Other Investing Activities | $-1.14B | $-251.00M | $1.59B | $-2.41B | $-230.00M | $-925.00M | $146.00M | $256.00M | $-335.00M | $204.00M | $-60.00M | $-531.00M | $251.00M | $-556.00M | $1.25B | $-787.00M | $-11.00M | $-165.00M | $-240.00M | $134.00M |
| Net Cash Used for Investing Activities | $-3.13B | $-13.69B | $-464.00M | $-1.20B | $2.54B | $-3.78B | $3.31B | $-4.40B | $-1.70B | $-2.64B | $-3.63B | $-5.36B | $-2.72B | $-419.00M | $-185.00M | $-7.90B | $-4.82B | $-7.52B | $-581.00M | $-1.34B |
| Debt Repayment | $-7.40B | $11.54B | $4.37B | $-1.05B | $-7.42B | $-7.10B | $12.88B | $- | $119.00M | $9.00M | $-2.13B | $-3.00M | $654.00M | $-189.00M | $-1.00B | $-2.80B | $7.20B | $2.71B | $-19.00M | $-1.94B |
| Common Stock Issued | $- | $- | $- | $- | $- | $4.50B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $-539.00M | $-136.00M | $-1.48B | $-216.00M | $-920.00M | $-381.00M | $-3.54B | $-1.32B | $-2.17B | $-973.00M | $-1.58B | $-996.00M | $-391.00M | $-631.00M | $-1.44B | $-321.00M | $-483.00M | $-706.00M | $-1.71B | $-426.00M |
| Dividends Paid | $-2.98B | $-2.98B | $-2.87B | $-2.87B | $-2.87B | $-3.09B | $-2.94B | $-2.95B | $-2.97B | $-2.97B | $-2.79B | $-2.79B | $-2.79B | $-2.79B | $-2.66B | $-2.66B | $-2.66B | $-2.66B | $-2.50B | $-2.50B |
| Other Financing Activities | $1.04B | $-878.00M | $516.00M | $-525.00M | $-105.00M | $338.00M | $-263.00M | $5.97B | $1.09B | $1.67B | $2.11B | $354.00M | $321.00M | $332.00M | $-28.00M | $134.00M | $134.00M | $299.00M | $-80.00M | $789.00M |
| Net Cash Used Provided by Financing Activities | $-9.88B | $7.54B | $546.00M | $-4.66B | $-11.32B | $-5.99B | $6.14B | $1.70B | $-3.92B | $-2.26B | $-4.38B | $-3.44B | $-2.21B | $-3.28B | $-5.12B | $-5.64B | $4.20B | $-357.00M | $-4.32B | $-4.07B |
| Effect of Forex Changes on Cash | $119.00M | $-85.00M | $-125.00M | $125.00M | $-168.00M | $-97.00M | $28.00M | $119.00M | $-286.00M | $-161.00M | $16.00M | $-53.00M | $-92.00M | $45.00M | $-78.00M | $224.00M | $31.00M | $71.00M | $-237.00M | $74.00M |
| Net Change in Cash | $-4.90B | $-595.00M | $3.61B | $2.13B | $-1.46B | $-5.68B | $12.74B | $2.77B | $372.00M | $520.00M | $-4.02B | $-3.12B | $3.27B | $1.66B | $-1.31B | $-4.98B | $7.79B | $-4.36B | $-1.77B | $1.06B |
| Cash at End of Period | $19.98B | $24.88B | $25.47B | $21.86B | $19.73B | $21.18B | $26.86B | $14.13B | $11.36B | $10.98B | $10.46B | $14.49B | $17.60B | $14.33B | $12.67B | $13.98B | $18.96B | $11.17B | $15.53B | $17.30B |
| Cash at Beginning of Period | $24.88B | $25.47B | $21.86B | $19.73B | $21.18B | $26.86B | $14.13B | $11.36B | $10.98B | $10.46B | $14.49B | $17.60B | $14.33B | $12.67B | $13.98B | $18.96B | $11.17B | $15.53B | $17.30B | $16.25B |
| Operating Cash Flow | $7.99B | $5.63B | $3.66B | $7.86B | $7.49B | $4.18B | $3.26B | $5.35B | $6.28B | $5.58B | $3.98B | $5.73B | $8.29B | $5.31B | $4.07B | $8.34B | $8.38B | $3.45B | $3.36B | $6.40B |
| Capital Expenditure | $-2.28B | $-976.00M | $-807.00M | $-1.59B | $-967.00M | $-1.12B | $-863.00M | $-1.59B | $-952.00M | $-863.00M | $-607.00M | $-1.42B | $-747.00M | $-813.00M | $-677.00M | $-1.32B | $-737.00M | $-662.00M | $-625.00M | $-1.26B |
| Free Cash Flow | $5.71B | $4.66B | $2.85B | $6.27B | $6.52B | $3.06B | $2.39B | $3.76B | $5.33B | $4.72B | $3.37B | $4.32B | $7.54B | $4.50B | $3.40B | $7.02B | $7.65B | $2.79B | $2.73B | $5.14B |
Johnson & Johnson Stock Forecast
Analyst ratings, price targets, and earnings estimates for JNJ.
JNJ Analyst Ratings
Moderate Buy
Based on 21 analysts in the past 3 months
JNJ Stock 12 Month Forecast
$166.00
▲
(8.14%
Upside)
Highest Price Target
$
(0.0%)
Average Price Target
$166.00
(8.1%)
Lowest Price Target
$
(0.0%)
Based on 1 analysts in the last 3 months
Recent Price Targets
Recommendation Trends
Analyst Estimates
Revenue Estimates
High
$91.43B
Average
$90.19B
Low
$89.68B
11 analysts
Net Income Estimates
High
$27.23B
Average
$27.09B
Low
$26.95B
11 analysts
EPS Estimates
High
$10.64
Average
$10.59
Low
$10.53
11 analysts
Revenue Estimates
High
$94.34B
Average
$93.41B
Low
$91.95B
14 analysts
Net Income Estimates
High
$29.26B
Average
$28.53B
Low
$27.81B
14 analysts
EPS Estimates
High
$11.43
Average
$11.05
Low
$10.86
11 analysts
Revenue Estimates
High
$97.31B
Average
$97.02B
Low
$96.74B
9 analysts
Net Income Estimates
High
$31.99B
Average
$29.52B
Low
$27.05B
9 analysts
EPS Estimates
High
$12.49
Average
$11.53
Low
$10.57
2 analysts
Revenue Estimates
High
$103.89B
Average
$102.03B
Low
$100.70B
3 analysts
Net Income Estimates
High
$32.04B
Average
$31.30B
Low
$30.77B
3 analysts
EPS Estimates
High
$12.51
Average
$12.22
Low
$12.02
1 analysts
Revenue Estimates
High
$108.38B
Average
$106.44B
Low
$105.06B
4 analysts
Net Income Estimates
High
$33.68B
Average
$32.90B
Low
$32.34B
4 analysts
EPS Estimates
High
$13.15
Average
$12.85
Low
$12.63
1 analysts
Latest Price Target Updates
| Date | Analyst | Firm | Price Target | Price When Posted | Upside |
|---|---|---|---|---|---|
| Feb 03, 2025 | Vamil Divan | Guggenheim | $166.00 | $151.87 | 9.3% |
| Oct 16, 2024 | Chris Shibutani | Goldman Sachs | $159.00 | $164.28 | -3.2% |
| Oct 16, 2024 | Terence Flynn | Morgan Stanley | $175.00 | $164.10 | 6.6% |
| Oct 16, 2024 | Shagun Singh | RBC Capital | $181.00 | $164.10 | 10.3% |
| Oct 16, 2024 | Joanne Wuensch | Citigroup | $185.00 | $164.10 | 12.7% |
| Oct 15, 2024 | Larry Biegelsen | Wells Fargo | $166.00 | $164.10 | 1.2% |
| Oct 15, 2024 | Rick Wise | Stifel Nicolaus | $170.00 | $164.10 | 3.6% |
| Oct 15, 2024 | Joanna Wuensch | Citigroup | $180.00 | $163.77 | 9.9% |
| Oct 14, 2024 | Louise Chen | Cantor Fitzgerald | $215.00 | $161.60 | 33.0% |
| Jul 23, 2024 | Narumi Nakagiri | Johnson Rice | $150.00 | $154.24 | -2.7% |
Johnson & Johnson Dividends
Explore Johnson & Johnson's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
2.96%
Dividend Payout Ratio
33.48%
Dividend Paid & Capex Coverage Ratio
1.40x
Johnson & Johnson Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $1.24 | $1.24 | February 18, 2025 | February 18, 2025 | March 04, 2025 | January 02, 2025 |
| $1.24 | $1.24 | November 26, 2024 | November 26, 2024 | December 10, 2024 | October 15, 2024 |
| $1.24 | $1.24 | August 27, 2024 | August 27, 2024 | September 10, 2024 | July 17, 2024 |
| $1.24 | $1.24 | May 20, 2024 | May 21, 2024 | June 04, 2024 | April 16, 2024 |
| $1.19 | $1.19 | February 16, 2024 | February 20, 2024 | March 05, 2024 | January 02, 2024 |
| $1.19 | $1.19 | November 20, 2023 | November 21, 2023 | December 05, 2023 | October 19, 2023 |
| $1.19 | $1.19 | August 25, 2023 | August 28, 2023 | September 07, 2023 | July 20, 2023 |
| $1.19 | $1.19 | May 22, 2023 | May 23, 2023 | June 06, 2023 | April 18, 2023 |
| $1.13 | $1.13 | February 17, 2023 | February 21, 2023 | March 07, 2023 | January 03, 2023 |
| $1.13 | $1.13 | November 21, 2022 | November 22, 2022 | December 06, 2022 | October 19, 2022 |
| $1.13 | $1.13 | August 22, 2022 | August 23, 2022 | September 06, 2022 | July 18, 2022 |
| $1.13 | $1.13 | May 23, 2022 | May 24, 2022 | June 07, 2022 | April 19, 2022 |
| $1.06 | $1.06 | February 18, 2022 | February 22, 2022 | March 08, 2022 | January 04, 2022 |
| $1.06 | $1.06 | November 22, 2021 | November 23, 2021 | December 07, 2021 | October 21, 2021 |
| $1.06 | $1.06 | August 23, 2021 | August 24, 2021 | September 07, 2021 | July 19, 2021 |
| $1.06 | $1.06 | May 24, 2021 | May 25, 2021 | June 08, 2021 | April 20, 2021 |
| $1.01 | $1.01 | February 22, 2021 | February 23, 2021 | March 09, 2021 | January 04, 2021 |
| $1.01 | $1.01 | November 23, 2020 | November 24, 2020 | December 08, 2020 | October 22, 2020 |
| $1.01 | $1.01 | August 24, 2020 | August 25, 2020 | September 08, 2020 | July 20, 2020 |
| $1.01 | $1.01 | May 22, 2020 | May 26, 2020 | June 09, 2020 | April 14, 2020 |
Peers: Drug Manufacturers - General
This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.
| Company | Market Cap | Price | EPS | P/E Ratio | P/B Ratio |
|---|---|---|---|---|---|
Merck & Co., Inc.
MRK
|
$222.73B | $88.05 | $0.14 | $778.71 | $7.56 |
Bristol-Myers Squibb Company
BMY
|
$116.46B | $57.42 | $3.88 | $13.23 | $3.61 |
Amgen Inc.
AMGN
|
$160.07B | $297.78 | $7.62 | $34.22 | $0.00 |
Pfizer Inc.
PFE
|
$146.38B | $25.83 | $0.38 | $76.67 | $1.83 |
AbbVie Inc.
ABBV
|
$341.01B | $192.97 | $2.75 | $56.34 | $26.45 |
Eli Lilly and Company
LLY
|
$826.26B | $870.37 | $5.83 | $100.04 | $48.67 |
Gilead Sciences, Inc.
GILD
|
$122.18B | $98.04 | $4.54 | $17.85 | $4.43 |
Related Metrics
Explore detailed financial metrics and analysis for JNJ.
Core Metrics
Income & Revenue
Returns & Ratios
Balance Sheet
Dividends
Financial Reports (10-Q, 10-K)
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Oct 23, 2024
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Jul 25, 2024
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 01, 2024
10-K
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 16, 2024
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Oct 27, 2023
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Jul 31, 2023
Current Reports (8-K)
8-K
Form 8-K - Current report - Item 2.02 Item 9.01
Jan 22, 2025
8-K
Form 8-K - Current report - Item 2.02 Item 9.01
Oct 15, 2024
8-K
Form 8-K - Current report - Item 7.01 Item 9.01
Sep 20, 2024
8-K
Form 8-K - Current report - Item 5.02
Sep 10, 2024
8-K
Form 8-K - Current report - Item 5.02
Aug 26, 2024
8-K
Form 8-K - Current report - Item 2.02 Item 9.01
Jul 17, 2024
8-K
Form 8-K - Current report - Item 8.01 Item 9.01
May 20, 2024
8-K
Form 8-K - Current report - Item 8.01
May 17, 2024
8-K
Form 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
May 01, 2024
8-K
Form 8-K - Current report - Item 5.03 Item 5.07 Item 9.01
Apr 29, 2024
8-K
Form 8-K - Current report - Item 2.02 Item 8.01 Item 9.01
Apr 16, 2024
8-K
Form 8-K - Current report - Item 2.02 Item 9.01
Jan 23, 2024
8-K
Form 8-K - Current report - Item 5.02
Dec 05, 2023
8-K
Form 8-K - Current report - Item 8.01
Dec 05, 2023
8-K
Form 8-K - Current report - Item 8.01
Nov 30, 2023
8-K
Form 8-K - Current report - Item 5.02
Nov 27, 2023
8-K
Form 8-K - Current report - Item 5.02
Oct 23, 2023
8-K
Form 8-K - Current report - Item 2.02 Item 9.01
Oct 17, 2023
8-K
Form 8-K - Current report - Item 2.02 Item 9.01
Aug 30, 2023
8-K
Form 8-K - Current report - Item 2.01
Aug 25, 2023
8-K
Form 8-K - Current report - Item 5.04 Item 9.01
Jul 28, 2023
Ownership
4
Form 4 - Statement of changes in beneficial ownership of securities
Dec 12, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Dec 12, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Dec 12, 2024
144
Form 144 - Report of proposed sale of securities
Dec 04, 2024
13F-HR
Form 13F-HR - Quarterly report filed by institutional managers, Holdings
Nov 13, 2024
SC 13G/A
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Nov 01, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Oct 21, 2024
SC 13G/A
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Oct 18, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Oct 15, 2024
3
Form 3 - Initial statement of beneficial ownership of securities
Oct 09, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Sep 12, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Sep 12, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Sep 03, 2024
144
Form 144 - Report of proposed sale of securities
Aug 30, 2024
13F-HR
Form 13F-HR - Quarterly report filed by institutional managers, Holdings
Aug 09, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Jul 09, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Jun 06, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Jun 06, 2024
SC 13G/A
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
May 20, 2024
13F-HR
Form 13F-HR - Quarterly report filed by institutional managers, Holdings
May 10, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
May 03, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Apr 29, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Apr 29, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Apr 29, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Apr 29, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Apr 29, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Apr 29, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Apr 29, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Apr 29, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Apr 29, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Apr 29, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Apr 29, 2024
3
Form 3 - Initial statement of beneficial ownership of securities
Apr 10, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Mar 13, 2024
144
Form 144 - Report of proposed sale of securities
Mar 13, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Mar 07, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Mar 07, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Mar 06, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 20, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 20, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 20, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 20, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 20, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 20, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 20, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 20, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 20, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 20, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 20, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 20, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 15, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 15, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 15, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 15, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 15, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 15, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 15, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 15, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 15, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 15, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 15, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 14, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 14, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 14, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 14, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 14, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 14, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 14, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 14, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 14, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 14, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 14, 2024
13F-HR
Form 13F-HR - Quarterly report filed by institutional managers, Holdings
Feb 13, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 13, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 13, 2024
SC 13G/A
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Feb 13, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 12, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 12, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 12, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 12, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 12, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 12, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 12, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 12, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 12, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 12, 2024
4
Form 4 - Statement of changes in beneficial ownership of securities
Feb 12, 2024
144
Form 144 - Report of proposed sale of securities
Feb 09, 2024
144
Form 144 - Report of proposed sale of securities
Feb 09, 2024
144
Form 144 - Report of proposed sale of securities
Feb 06, 2024
SC 13G/A
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Feb 02, 2024
SC 13G/A
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Feb 02, 2024
SC 13G/A
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Feb 02, 2024
SC 13G/A
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Jan 30, 2024
SC 13G/A
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Jan 26, 2024
3
Form 3 - Initial statement of beneficial ownership of securities
Dec 08, 2023
4
Form 4 - Statement of changes in beneficial ownership of securities
Dec 07, 2023
13F-HR
Form 13F-HR - Quarterly report filed by institutional managers, Holdings
Nov 09, 2023
3
Form 3 - Initial statement of beneficial ownership of securities
Nov 02, 2023
4
Form 4 - Statement of changes in beneficial ownership of securities
Sep 11, 2023
4
Form 4 - Statement of changes in beneficial ownership of securities
Aug 25, 2023
4
Form 4 - Statement of changes in beneficial ownership of securities
Aug 25, 2023
4
Form 4 - Statement of changes in beneficial ownership of securities
Aug 25, 2023
4
Form 4 - Statement of changes in beneficial ownership of securities
Aug 25, 2023
4
Form 4 - Statement of changes in beneficial ownership of securities
Aug 25, 2023
4
Form 4 - Statement of changes in beneficial ownership of securities
Aug 25, 2023
13F-HR
Form 13F-HR - Quarterly report filed by institutional managers, Holdings
Aug 02, 2023
4
Form 4 - Statement of changes in beneficial ownership of securities
Jul 27, 2023
Prospectuses & Registrations
25-NSE
Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
Nov 06, 2024
8-A12B
Form 8-A12B - Registration of securities [Section 12(b)]
May 20, 2024
25-NSE
Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
May 20, 2024
424B2
Form 424B2 - Prospectus [Rule 424(b)(2)]
May 16, 2024
424B2
Form 424B2 - Prospectus [Rule 424(b)(2)]
May 15, 2024
FWP
Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
May 14, 2024
FWP
Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
May 13, 2024
ARS
Form ARS - Annual Report to Security Holders
Mar 13, 2024
Proxy Statements
PX14A6G
Form PX14A6G - Notice of exempt solicitation submitted by non-management
Mar 27, 2024
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 13, 2024
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 13, 2024
DEF 14A
Form DEF 14A - Other definitive proxy statements
Mar 13, 2024
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jan 08, 2024